CGTBiologicstaleNational Taiwan University Hosp…Phase 1
CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)
Relapsed/Refractory B-Cell Malignancies · CD19
#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 67%임상시험 1상태 ACTIVE